Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

GLOBAL BIOTECHNOLOGY REAGENTS MARKET – ABBOTT, BECKMAN COULTER, AGILENT TECHNOLOGIES INC., WATER CORPORATION, BIORAD, ROCHE, SIGMA-ALDRICH

Abbott | November 29, 2016

news image

Biotechnology Reagents Market by Technology (Chromatography, Electrophoresis, PCR, Mass Spectrometry, Flow Cytometry, Expression & Transfection) for DNA & RNA Analysis, Protein Purification, Drug Testing, Gene Expression and by End user: Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 – 2021.Global biotechnology reagents market is expected to reach USD 94.6 billion in 2021, growing at a CAGR of 9.0% during 2016 and 2021....

Read More

SHIRE FILES INJUNCTION AGAINST ROCHE HEMOPHILIA COMPETITOR

biopharmadive | July 10, 2017

news image

In an unexpected move, Shire International has secured an injunction in a Hamburg, Germany court against Roche for the Swiss pharma's as yet unmarketed hemophilia drug, emicizumab. The injunction claims Roche is disseminating "inaccurate and misleading characterization of the serious adverse events that occurred in the HAVEN 1 Phase 3 trial of emicizumab, as well as misinformation about "the appropriate management of breakthrough bleeds uncontrolled by emicizumab....

Read More

CLEMENTIA FILES FOR $115M IPO TO FUND LATE-PHASE TRIALS OF EX-ROCHE DRUG IN ULTRARARE GENETIC BONE DISEASES

fiercebiotech | July 05, 2017

news image

Clementia Pharmaceuticals has filed to raise $115 million in an IPO. The Canadian biotech wants the cash to bankroll late-phase trials of an oral retinoic acid receptor gamma agonist it licensed from Roche. Montreal, Canada-based Clementia intends to use the IPO money to take the former Roche drug, palovarotene, through two phase 3 trials in fibrodysplasia ossificans progressiva (FOP). If the data are good, Clementia plans to file for approval and make palovarotene the go-to drug for the ...

Read More

A FUTURE GENE THERAPY COULD BE DELIVERED IN TINY ‘NANOCONTAINERS’

Labiotech.eu | January 28, 2020

news image

A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient at their job, viral vectors can risk triggering the immune system to destroy them. This can lead to the therapy becoming ineffective....

Read More
news image

GLOBAL BIOTECHNOLOGY REAGENTS MARKET – ABBOTT, BECKMAN COULTER, AGILENT TECHNOLOGIES INC., WATER CORPORATION, BIORAD, ROCHE, SIGMA-ALDRICH

Abbott | November 29, 2016

Biotechnology Reagents Market by Technology (Chromatography, Electrophoresis, PCR, Mass Spectrometry, Flow Cytometry, Expression & Transfection) for DNA & RNA Analysis, Protein Purification, Drug Testing, Gene Expression and by End user: Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 – 2021.Global biotechnology reagents market is expected to reach USD 94.6 billion in 2021, growing at a CAGR of 9.0% during 2016 and 2021....

Read More
news image

SHIRE FILES INJUNCTION AGAINST ROCHE HEMOPHILIA COMPETITOR

biopharmadive | July 10, 2017

In an unexpected move, Shire International has secured an injunction in a Hamburg, Germany court against Roche for the Swiss pharma's as yet unmarketed hemophilia drug, emicizumab. The injunction claims Roche is disseminating "inaccurate and misleading characterization of the serious adverse events that occurred in the HAVEN 1 Phase 3 trial of emicizumab, as well as misinformation about "the appropriate management of breakthrough bleeds uncontrolled by emicizumab....

Read More
news image

CLEMENTIA FILES FOR $115M IPO TO FUND LATE-PHASE TRIALS OF EX-ROCHE DRUG IN ULTRARARE GENETIC BONE DISEASES

fiercebiotech | July 05, 2017

Clementia Pharmaceuticals has filed to raise $115 million in an IPO. The Canadian biotech wants the cash to bankroll late-phase trials of an oral retinoic acid receptor gamma agonist it licensed from Roche. Montreal, Canada-based Clementia intends to use the IPO money to take the former Roche drug, palovarotene, through two phase 3 trials in fibrodysplasia ossificans progressiva (FOP). If the data are good, Clementia plans to file for approval and make palovarotene the go-to drug for the ...

Read More
news image

A FUTURE GENE THERAPY COULD BE DELIVERED IN TINY ‘NANOCONTAINERS’

Labiotech.eu | January 28, 2020

A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient at their job, viral vectors can risk triggering the immune system to destroy them. This can lead to the therapy becoming ineffective....

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us